All In Biotech

Drug Trial Radar · NCT07925619

Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers

A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of L608 Suspension in Patients With Systemic Sclerosis-associated Digital Ulcers

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Feb 1, 2027

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Pharmosa Biopharm Inc.Industry
Sponsor type
Industry
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is designed to evaluate the efficacy and safety of L608 compared to placebo in patients with SSc-DU.

Conditions

  • Systemic Sclerosis

Interventions

  • L608Drug

    Participants will receive L608 TID over 28 consecutive days.

  • PlaceboDrug

    Participants will receive Placebo TID over 28 consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to healing of the cardinal DUTime frame: up to 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.